Novartis says no to PBAC deal
By Megan Brodie 1 year ago | In Companies, Patients, Products, Reimbursement- 1 year ago
15 August 2025 Novartis has walked away from a PBAC recommendation for its CGRP inhibitor…
This is subscriber-only content. Please login to continue reading.